CD274 and neoplasm: Atezolizumab selectively binds to PD-L1, blocks the PD-1/PD-L1 signaling pathway, enhances the recognition of tumor cells by immune cells T cells in the body, and kills tumor cells after T cell activation (Huppert et al., 2020).